Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMACPQO)

Drug Name
Dihydrexidine Drug Info
Synonyms
DIHYDREXIDINE; (+)-Dihydrexidine; UNII-Q3PJ4B4D0X; Q3PJ4B4D0X; CHEMBL25856; Dihydrexidine hydrochloride; (6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol; (6aR,12bS)-5,6,6a,7,8,12b-Hexahydrobenzo(a)phenanthridine-10,11-diol; Rel-Dihydrexidine; Dihydrexidine, (+)-; Lopac-D-5814; Biomol-NT_000033; AC1O7G2G; Lopac0_000380; 5,6,6a,7,8,12b-Hexahydro-benzo[a]phenanthridine-10,11-diol; BPBio1_001227; SCHEMBL4614575; CHEBI:124993; DAR-0100; IP-202; BDBM50010686; ZINC25758512; CCG-204474; NCGC00024845-04
Cross-matching ID
PubChem CID
5311070
CAS Number
CAS 123039-93-0
TTD Drug ID
D0D3VT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Histidine metabolism 1.95 5.23e-3 16/22 (72.73%) ALDH2;ASPA;MAOB;...
DNA replication 1.92 2.62e-3 34/36 (94.44%) RFC2;DNA2;FEN1;...
Ribosome biogenesis in eukaryotes 1.89 1.74e-3 52/108 (48.15%) IMP3;POP5;NOP56;...
Spliceosome 1.82 1.44e-2 101/150 (67.33%) PRPF19;FUS;LSM4;...
Base excision repair 1.71 4.50e-2 29/33 (87.88%) APEX1;TDG;FEN1;...
Other glycan degradation -1.67 2.52e-2 13/18 (72.22%) FUCA1;NEU1;GLB1;...
Nicotine addiction -1.68 2.34e-2 32/40 (80%) SLC17A7;GABRA1;GRIN2C;...
Biosynthesis of unsaturated fatty acids -1.68 2.43e-2 21/27 (77.78%) ELOVL6;HACD2;ACOX1;...
Non-small cell lung cancer -1.69 2.35e-2 70/72 (97.22%) SOS1;FOXO3;PDPK1;...
Salivary secretion -1.69 2.32e-2 76/93 (81.72%) ATP1A2;SLC9A1;GUCY1B1;...
Cholinergic synapse -1.71 1.93e-2 99/113 (87.61%) CACNA1D;GNAO1;MAP2K1;...
Morphine addiction -1.71 2.01e-2 80/91 (87.91%) GABRA4;PDE3A;PDE1B;...
Dopaminergic synapse -1.71 2.10e-2 115/132 (87.12%) MAOA;PRKACG;KCNJ5;...
Amphetamine addiction -1.72 2.20e-2 57/69 (82.61%) CREB3L2;TH;PPP1CA;...
GnRH signaling pathway -1.72 2.23e-2 80/93 (86.02%) CACNA1D;MAP2K1;GNAQ;...
Colorectal cancer -1.72 2.26e-2 84/86 (97.67%) MAP2K1;MSH3;TCF7;...
Arrhythmogenic right ventricular cardiomyopathy -1.73 2.07e-2 70/77 (90.91%) ITGB5;CACNA2D1;CACNA1C;...
Renal cell carcinoma -1.73 2.18e-2 68/69 (98.55%) EP300;HIF1A;RBX1;...
HIF-1 signaling pathway -1.75 1.78e-2 105/109 (96.33%) EP300;HIF1A;RBX1;...
Retrograde endocannabinoid signaling -1.76 1.89e-2 118/148 (79.73%) GNAI3;GNG4;PRKACA;...
Bacterial invasion of epithelial cells -1.78 1.71e-2 59/77 (76.62%) PIK3CA;ITGA5;ITGB1;...
Oxidative phosphorylation -1.79 1.62e-2 93/133 (69.92%) ATP6AP1;COX7A1;ATP5PO;...
Circadian entrainment -1.81 1.28e-2 85/97 (87.63%) GNAI3;GNG4;PRKACA;...
Relaxin signaling pathway -1.82 1.38e-2 114/129 (88.37%) GNAO1;MAP2K1;INSL5;...
Cardiac muscle contraction -1.82 1.51e-2 64/87 (73.56%) MYL3;CACNA2D1;CACNA1C;...
Glutamatergic synapse -1.84 1.21e-2 97/114 (85.09%) SLC1A1;GRM5;SLC38A1;...
GABAergic synapse -1.87 8.39e-3 76/89 (85.39%) GABBR1;GLUL;GABRA6;...
Long-term potentiation -1.88 9.43e-3 61/67 (91.04%) GRM1;EP300;PPP1CA;...
Vibrio cholerae infection -1.91 6.47e-3 44/50 (88%) KDELR3;GNAS;SEC61G;...
ErbB signaling pathway -1.92 7.55e-3 79/85 (92.94%) MAP2K1;TGFA;RPS6KB1;...
Renin secretion -1.93 9.06e-3 61/69 (88.41%) GUCY1B1;PDE3B;CACNA1D;...
Estrogen signaling pathway -1.93 7.55e-3 119/137 (86.86%) KRT24;GNAO1;MAP2K1;...
Steroid biosynthesis -1.94 1.01e-2 19/20 (95%) CYP51A1;HSD17B7;DHCR7;...
Mineral absorption -2.00 7.55e-3 48/60 (80%) SLC31A1;MT1E;FTL;...
Ferroptosis -2.32 0.00e+0 36/41 (87.8%) SLC3A2;ACSL3;ACSL5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H